Literature DB >> 9572407

Endocrino-metabolic features in women with polycystic ovary syndrome during pregnancy.

G Paradisi1, A M Fulghesu, S Ferrazzani, S Moretti, C Proto, L Soranna, A Caruso, A Lanzone.   

Abstract

To elucidate the mechanism of metabolic adaptation of women with polycystic ovary syndrome (PCOS) during pregnancy, the endocrino-metabolic features of a group of PCOS patients with or without gestational diabetes were studied longitudinally during the three trimesters of gestation. Oral glucose tolerance test (OGTT, 100 g) and hyperinsulinaemic-euglycaemic clamp were performed throughout the study. Plasma concentrations of insulin and glucose were determined by radioimmunoassay and glucose oxidase technique, respectively. Five of 13 PCOS patients developed gestational diabetes (GD) at the third trimester (PCOS-GD), while the other eight patients did not develop any alteration of glucose metabolism (PCOS-nGD). Both fasting glucose and insulin plasma concentrations did not change significantly during pregnancy and no difference was seen between the two groups. On the contrary PCOS-GD group early exhibited higher values of area under the curve (AUC) for glucose and insulin response to OGTT with respect to those found in PCOS-nGD group. This difference was already significant in the first gestational trimester. Moreover insulin sensitivity value (M) was significantly lower in the first trimester of gestation in PCOS-GD as compared with that found in PCOS-nGD group. However, as gestation proceeded, M value decreased in PCOS-nDG group and the difference from PCOS patients developing gestational diabetes was not sustained into the second and third trimesters. Both groups had similar body mass index values and AUC insulin increase from first to third trimester of gestation. It is concluded that early alteration of insulin sensitivity and secretion constitute specific risk factors in PCOS patients for the development of abnormalities of glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572407     DOI: 10.1093/humrep/13.3.542

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Late pregnancy complications in polycystic ovarian syndrome.

Authors:  I Katsikis; M Kita; A Karkanaki; N Prapas; D Panidis
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

2.  Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels.

Authors:  Helen Anderson; Naomi Fogel; Stefan K Grebe; Ravinder J Singh; Robert L Taylor; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2010-03-12       Impact factor: 5.958

3.  TyGIS: improved triglyceride-glucose index for the assessment of insulin sensitivity during pregnancy.

Authors:  Benedetta Salvatori; Tina Linder; Daniel Eppel; Micaela Morettini; Laura Burattini; Christian Göbl; Andrea Tura
Journal:  Cardiovasc Diabetol       Date:  2022-10-18       Impact factor: 8.949

4.  Longitudinal metabolic observation of metformin effects during pregnancy in hyperinsulinemic women with polycystic ovary syndrome: a case report.

Authors:  M Guido; D Romualdi; C Belosi; L Selvaggi; A Lanzone
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

5.  Intergenerational associations of chronic disease and polycystic ovary syndrome.

Authors:  Michael J Davies; Jennifer L Marino; Kristyn J Willson; Wendy A March; Vivienne M Moore
Journal:  PLoS One       Date:  2011-10-04       Impact factor: 3.240

6.  Relationship between Polycystic Ovarian Syndrome and Subsequent Gestational Diabetes Mellitus: A Nationwide Population-Based Study.

Authors:  Mei-Lien Pan; Li-Ru Chen; Hsiao-Mei Tsao; Kuo-Hu Chen
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

7.  How metformin acts in PCOS pregnant women: insights into insulin secretion and peripheral action at each trimester of gestation.

Authors:  Daniela Romualdi; Simona De Cicco; Donatella Gagliano; Matteo Busacca; Giuseppe Campagna; Antonio Lanzone; Maurizio Guido
Journal:  Diabetes Care       Date:  2013-01-11       Impact factor: 19.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.